News

Filter

Resubmission expected for Orexigen's obesity drug Contrave

29-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Obesity drug market set to grow to $2.6 billion by 2020, says DR report

27-09-2011

The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

Vivus plummets 62% as FDA advisory meeting rejects approval of its obesity drug Qnexa

16-07-2010

In a fairly unexpected decision, a US Food and Drug Administration advisory panel yesterday voted 10…

Arena PharmaceuticalsContravelorcaserinMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Back to top